Document is current
Any future updates will be listed below
-
Authors
Li, Chao
Hart, Lowell
Owonikoko, Taofeek K.
Aljumaily, Raid
Rocha Lima, Caio Max
Conkling, Paul R.
Webb, Roy Timothy
Jotte, Robert M.
Schuster, Steven
Edenfield, William J.
Smith, Deborah A.
Sale, Mark
Roberts, Patrick J.
Malik, Rajesh K. https://orcid.org/0000-0002-9661-9347
Sorrentino, Jessica A.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02243150 at ClinicalTrials.govnct02499770 at ClinicalTrials.govDocuments that mention this clinical trial
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
https://doi.org/10.1007/s00280-021-04239-9
nct02514447 at ClinicalTrials.govDocuments that mention this clinical trial
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
https://doi.org/10.1007/s00280-021-04239-9
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
https://doi.org/10.1136/jitc-2020-000847
Documents that mention this clinical trial
Pharmacokinetic Drug–Drug Interaction Studies Between Trilaciclib and Midazolam, Metformin, Rifampin, Itraconazole, and Topotecan in Healthy Volunteers and Patients with Extensive-Stage Small-Cell Lung Cancer
https://doi.org/10.1007/s40261-022-01179-x
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
https://doi.org/10.1007/s00280-021-04239-9
-
Funding
Funding for this research was provided by:
G1 Therapeutics, Inc.
- License Information
-
More Information
Article History
Received: 13 November 2020
Accepted: 28 January 2021
First Online: 17 February 2021
Compliance with ethical standards
:
: Chao Li: employee of G1 Therapeutics, Inc. at time of study. Lowell Hart: consultancy fees and research funding to institution from G1 Therapeutics, Inc. Taofeek K. Owonikoko: none to declare regarding this work. Raid Aljumaily: none to declare regarding this work. Caio Max Rocha Lima: none to declare regarding this work. Paul R. Conkling: research funding from Ignyta, Roche, BMS, Arcus Bioscience, Janssen, Aptose, and US Oncology Research. Roy Timothy Webb: none to declare regarding this work. Robert M. Jotte: none to declare regarding this work. Steven Schuster: none to declare regarding this work. William J. Edenfield: consultancy fees from Chimerix. Deborah A. Smith: consultancy fees from G1 Therapeutics, Inc. Mark Sale: consultancy fees from G1 Therapeutics, Inc. Patrick J. Roberts: employee of G1 Therapeutics, Inc. at time of study. Rajesh K. Malik: employee of G1 Therapeutics, Inc. Jessica A. Sorrentino: employee of G1 Therapeutics, Inc.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: All patients provided written informed consent before entering the study.
